Whether differences in the level of absorption of rifamycin antibiotics in the gut of TB infected persons contribute to the different CYP3A4 induction pattern of rifamycin drugs in “in vivo” studies is unclear. This evidence concerns the gene CYP3A4 and tuberculosis.